8-K ·Filed Jun 24, 2026

PGEN

PRECIGEN, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0000950103-26-009441
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No immediate trading catalyst. The 7M share increase is standard equity compensation runway for a ~$1.9B market cap company. Monitor the next 10-Q for actual share issuance under the plan and any potential dilution impact.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
PGEN ▲ +40.94% at T+60d
NEUTRAL call ✓ call won +40.94% · α vs SPY +37.21% · entry $5.52 → $7.78
Entry anchored
Jun 24, 03:59 PM ET
via exchange tick
T+1d
+6.16%
call +6.16% · α +6.88%
$5.86
settled 3mo ago
T+5d
-4.89%
call -4.89% · α -6.45%
$5.25
settled 3mo ago
T+20d
+0.36%
call +0.36% · α -0.17%
$5.54
settled 2mo ago
T+60d
+40.94%
call +40.94% · α +37.21%
$7.78
settled 14d ago

Price Chart

Loading chart...

Executive Summary

Precigen filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. Stockholders approved all proposals, including the election of nine director nominees, ratification of Deloitte & Touche as auditor, a non-binding advisory vote on executive compensation, and an amendment to the 2023 Omnibus Incentive Plan to increase the share reserve by 7 million shares. This is a routine governance filing with no material financial impact.

Key Facts

  • All nine director nominees were elected with strong support (lowest 'For' vote was 153.1M for Vinita Gupta, with 57.9M against).
  • Deloitte & Touche LLP ratified as independent auditor for FY 2026 with 272.8M votes for, 254K against.
  • Non-binding advisory resolution on executive compensation approved with 208.2M for, 2.8M against.
  • Amendment to the 2023 Omnibus Incentive Plan approved, increasing shares available for issuance by 7 million.
  • No departures or appointments of directors or officers were reported; Item 5.02 only covers the plan amendment approval.

Financial Impact

No financial impact. The 7 million share increase under the 2023 Plan is a routine authorization for future equity awards, not an immediate issuance.

dilution

Risk Factors

  • Potential future dilution from equity awards granted under the expanded 2023 Plan.
  • Vinita Gupta's 27% vote against (57.9M shares) may indicate some shareholder dissent, though not material.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000950103-26-009441
Document: 0000950103-26-009441-index-headers.html0000950103-26-009441
Document: 0000950103-26-009441-index.html0000950103-26-009441
Document: 0000950103-26-009441.txt0000950103-26-009441
12 reports for PGEN
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +52.17%May 13, 2026
Filters
Rows
Reports for PGEN — sortable, filterable
TypeNow
Aug 29, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.93 $7.94▲ +14.57%▲ +14.51%$8.30 (+19.70%)
Aug 26, 2026
5w ago
144
NEUTRAL ★ 3/10
$7.19 $7.70▲ +7.09%▲ +7.60%$8.30 (+15.37%)
Aug 25, 2026
5w ago
Insider Cluster
BEARISH ★ 4/10
$7.42 $7.70▼ −3.77%▼ −3.55%$8.30 (−11.79%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.42 $7.70▲ +3.77%▲ +3.55%$8.30 (+11.79%)
Aug 7, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.00 $6.87▼ −1.86%▼ −0.94%$8.30 (+18.50%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$6.53 $6.86▲ +5.05%▲ +6.29%$8.30 (+27.03%)
Jul 1, 2026
13w ago
Insider Cluster
BEARISH ★ 5/10
$5.64 $5.94▼ −5.32%▼ −5.73%$8.30 (−47.07%)
Jun 24, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$5.52 $5.54▲ +0.36%▼ −0.17%$8.30 (+50.27%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.86 $5.25▲ +36.01%▲ +37.58%$8.30 (+114.90%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.86 $5.25▲ +36.01%▲ +37.58%$8.30 (+114.90%)
Showing 10 of 12

US Market Status

Market Open — Closes in 3h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access